Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients get continued access to promising targeted therapy

NCT ID NCT03194893

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after their original study ends. Participants must have been enrolled in a prior Roche-sponsored alectinib study and still be getting clinical benefit from the treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple endocrine neoplasia type 2A neoplasm non-small cell lung carcinoma RET fusion positive cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

  • Adana Ac?badem Hospital Oncology Department

    Adana, 01130, Turkey (Türkiye)

  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia

    Perugia, Umbria, 06132, Italy

  • Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1

    Rome, Lazio, 00151, Italy

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Tuscany, 50139, Italy

  • CHU de Toulouse - Hôpital Larrey

    Toulouse, 31059, France

  • Centre Francois Baclesse

    Caen, 14076, France

  • Centre Georges François Leclerc

    Dijon, 21000, France

  • Centre Leon Berard

    Lyon, 69008, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Chao Family Comprehensive Cancer Center

    Orange, California, 92868, United States

  • City Clinical Oncology Hospital

    Moscow, Moscow Oblast, 143423, Russia

  • Ege University Medical Faculty

    Izmir, 35040, Turkey (Türkiye)

  • FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"

    Moscow, Moscow Oblast, 115478, Russia

  • Groupe Hospitalier Sud - Hôpital Haut Lévêque

    Pessac, 33600, France

  • Hacettepe Uni Medical Faculty Hospital

    S?hhiye, Ankara, 06100, Turkey (Türkiye)

  • Hopital Pontchaillou - CHU de Rennes

    Rennes, 35033, France

  • Hopital Robert Schuman

    Vantoux, 57070, France

  • Hospital Universitari Dexeus - Grupo Quironsalud

    Barcelona, 08028, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital del Mar

    Barcelona, 08003, Spain

  • Irccs Centro Di Riferimento Oncologico (CRO)

    Aviano, Friuli Venezia Giulia, 33081, Italy

  • Istanbul Uni Capa Medical Faculty

    Istanbul, 34093, Turkey (Türkiye)

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • Queen Elizabeth Hospital Department of Clinical Oncology

    Kowloon, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • University ?linic of headaches

    Moscow, Moscow Oblast, 121467, Russia

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, 80-214, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.